Accelerated aging biomarkers linked to higher pancreatic disease risk
In a study of over 326,000 UK adults, measures of accelerated biological aging were associated with increased risk of pancreatic diseases, including cancer and chronic pancreatitis. Blood lipid levels partially explained this association.
Why it matters: These findings may help identify people at higher risk of pancreatic disease through aging measurements, though aging acceleration is not proven to cause these diseases.
Keep in mind: This is an observational study showing correlation, not proof that accelerated aging causes pancreatic disease; other unmeasured factors could explain the link.
AI-assisted explanation based on the supplied abstract. Read the linked source for full context.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 326,873
- Duration
- —
- Population
- Adults recruited to UK Biobank in 2006-2010
- Primary outcome
- Association between biological age acceleration and pancreatic disease risk
- Effect size
- PhenoAgeAccel G4 vs G1 for all pancreatic diseases: HR 1.706 (95% CI 1.513-1.923); acute pancreatitis: HR 1.637 (95% CI 1.352-1.981); chronic pancreatitis: HR 3.551 (95% CI 2.248-5.609); pancreatic cysts: HR 1.547 (95% CI 1.128-2.122); pancreatic cancer: HR 1.387 (95% CI 1.123-1.713); pancreas-related mortality: HR 1.442 (95% CI 1.139-1.824)
- Significance
- Significant
- Journal
- The journal of nutrition, health & aging
- Published
- Sep 15, 2026
Sources
Primary source
- The journal of nutrition, health & aging ↗Peer reviewed
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.